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ABSTRACT
Recent research demonstrates that transfusing whole 
blood (WB=red blood cells (RBC)+plasma+platelets) rather 
than just RBC (which is current National Health Service 
(NHS) practice) may improve outcomes for major trauma 
patients. As part of a programme to investigate provision 
of WB, NHS Blood and Transplant undertook a 2- year 
feasibility study to supply the Royal London Hospital (RLH) 
with (group O negative, ‘O neg’) leucodepleted red cell and 
plasma (LD- RCP) for transfusion of trauma patients with 
major haemorrhage in prehospital settings.
Incidents requiring such prehospital transfusion occur 
randomly, with very high variation. Availability is critical, 
but O neg LD- RCP is a scarce resource and has a limited 
shelf life (14 days) after which it must be disposed of. 
The consequences of wastage are the opportunity cost 
of loss of overall treatment capacity across the NHS and 
reputational damage.
The context was this feasibility study, set up to assess 
deliverability to RLH and subsequent wastage levels. 
Within this, we conducted a quality improvement project, 
which aimed to reduce the wastage of LD- RCP to no more 
than 8% (ie, 1 of the 12 units delivered per week).
Over this 2- year period, we reduced wastage from a 
weekly average of 70%–27%. This was achieved over 
four improvement cycles. The largest improvement came 
from moving near- expiry LD- RCP to the emergency 
department (ED) for use with their trauma patients, with 
subsequent improvements from embedding use in ED as 
routine practice, introducing a dedicated LD- RCP delivery 
schedule (which increased the units ≤2 days old at delivery 
from 42% to 83%) and aligning this delivery schedule to 
cover two cycles of peak demand (Fridays and Saturdays).
PROBLEM
There is evidence that transfusing whole 
blood (WB) for resuscitation of bleeding 
patients associated with trauma may be 
better than red blood cell (RBC) transfusion. 
However, manufacturing WB in the UK is 
technically difficult, the product has a shorter 
shelf life than RBC (14 vs 35 days) and the 
raw material (donated O negative (O neg) 
blood) is in short supply.
The Royal London Hospital (RLH) is part 
of Barts Health National Health Service 
(NHS) Trust. The hospital is one of the four 
major trauma centres (MTCs) in London 
and hosts the base for London’s Air Ambu-
lance (LAA) service. LAA operates the Heli-
copter Emergency Medical Service (HEMS), 
which provides prehospital advanced- trauma 
care across the whole region covered by the 
London MTCs. Their helicopters and rapid- 
response cars carry blood in Golden Hour 
boxes for transfusion. Over the last 4 years, 
they have administered a mean of 7.28 units 
of RBC per week (SD 2.60 units).
As part of the WB Feasibility Programme, in 
November 2018, NHS Blood and Transplant 
(NHSBT) started supplying RLH with (type 
O neg) leucodepleted red cell and plasma 
(LD- RCP) for use in the prehospital setting 
to treat major traumatic haemorrhage. In 
conjunction with this, RLH and HEMS made 
a clinical decision to change standard treat-
ment from RBC to LD- RCP for the manage-
ment of prehospital trauma patients who are 
bleeding.
By its nature, the availability of blood for 
prehospital transfusion is critical for patient 
outcomes,1 and the demand for it is highly 
variable (our baseline prehospital weekly 
demand data have a coefficient of variation of 
57%, which is higher than the benchmark for 
randomness represented by a Poisson distri-
bution with the same mean).
There is a fine balance between supply 
and demand: ensuring that we have enough 
LD- RCP (or, potentially, eventually WB) for all 
prehospital trauma patients while minimising 
wastage. This product is manufactured from 
group O neg blood donations in particular 
short supply, and has a relatively short shelf 
life (14 days, after which it must be disposed 
of), and as part of the study, it was targeted 
at a limited group of patients. Wastage could 
therefore be high and result in significant 
loss to the NHS: financial and in treatment 
capacity. Minimising LD- RCP wastage would 
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be crucial in deciding the feasibility of introducing a WB 
component nationally.
During set- up agreements for the feasibility study, 
supply of LD- RCP to RLH was agreed at 12 units per 
week. This being a new product, with short shelf life and 
targeted use, we had only been able to speculate about 
the potential level of wastage and what should be consid-
ered acceptable. The initial prestudy target wastage level 
was set (optimistically) at 8% on average. Higher wastage 
then could trigger reassessment of the WB Programme. 
The aim of the quality improvement (QI) work described 
in this paper was to achieve this low wastage rate by the 
end of the 24- month feasibility study. We used the Model 
for Improvement2 as a guiding framework. Later sections 
detail the metrics and change ideas. We used Plan–Do–
Study–Act (PDSA) cycles of learning and improvement 
to test, adapt and implement our change ideas, with run 
and Statistical Process Control (SPC) charts to investigate 
system performance and demonstrate impacts.
Once the project started, we found that initial (base-
line) wastage was very high (70%) and that many units 
had limited shelf life remaining at delivery (only 42% 
were age ≤2 days old and so having at least 12 days of 
opportunity for use). It became evident, therefore, that 
very considerable improvements were necessary.
BACKGROUND
There are four components of WB of importance in 
this paper: RBC, white blood cells (WBC or leucocytes), 
plasma and platelets, in the following combinations:
 ► RBC+plasma+platelets+WBC: WB, as donated blood.
 ► RBC (leucodepleted, LD): currently supplied to front-
line NHS units for transfusion.
 ► RBC+plasma (LD): LD- RCP, as supplied in the feasi-
bility study context here.
 ► RBC+plasma+platelets (LD): LD- WB, ideal WB 
component in development.
In the UK, all blood components are manufactured by 
NHSBT, who supply RBC, platelets and plasma for blood 
transfusion throughout the NHS.
Over the last decade, research has advanced our under-
standing of how the ratios of blood components trans-
fused affect outcomes in trauma patients. Clinical trials 
have demonstrated that early and continuous resuscita-
tion with RBC+fresh frozen plasma+platelets (in a 1:1:1 
ratio, resembling WB) reduces mortality.1 3 Therefore, in 
the UK, there is currently great interest in reintroducing 
a WB component for resuscitation of patients with trau-
matic major bleeding, particularly those presenting in 
prehospital settings.
To reduce the risk of variant CJD (Creutzfeldt- Jakob 
Disease) transmission, NHSBT removes WBC (leuco-
cytes) from WB through LD filters. The LD filter currently 
used by NHSBT also removes platelets. So, in addition to 
the individual components (RBC, platelets and plasma), 
NHSBT can produce LD- RCP (RBC+plasma in the same 
bag). NHSBT is currently assessing platelet- sparing LD 
filters to enable manufacture of safe WB (LD- WB).4
However, both LD- RCP and LD- WB have a much shorter 
shelf life than RBC: 14 days compared with 35 days. In the 
USA, unused WB is reprocessed after 10 days to produce 
RBC,5 avoiding blood component wastage. However, this 
is not possible in the UK due to regulatory constraints on 
hospital blood banks and hospital blood establishments, 
so in the NHS, there is risk of wastage.
Group O RhD Negative (‘O neg’) is considered the 
safest group to transfuse to patients with unknown blood 
groups. In addition to LD- RCP, O neg donations are also 
required for the manufacture of O neg RBC used for the 
transfusion of group O neg patients and for neonatal 
and for emergency transfusion of patients with acute 
bleeding requiring urgent resuscitation. In the UK, 12% 
of the demand for RBC is for O neg, but this group makes 
up only 8% of the population,6 so there is a shortage of 
donors and so of supply of this group6; donated O neg 
blood is a precious resource for the NHS.
MEASUREMENT
The global metric (or key performance indicator, KPI) 
was the wastage of LD- RCP (ie, the number of units that 
had to be disposed of at expiry of their shelf life) in 
units per week (and equivalently this as a percentage of 
the 12 units delivered per week). We realised an impor-
tant internal (or process) metric was the age of LD- RCP 
units at delivery. We agreed a benchmark with NHSBT 
of 2 days old based on pre- existing logistical processes, so 
the metric was percentage with age ≤2 days old at delivery.
Data were collected retrospectively from the laboratory 
information management system at RLH, WinPath. These 
data were analysed on a 1- week cycle and presented in 
the form of a dashboard including run and SPC charts.2 7
In the first phase of this QI programme, we established 
the current condition8 of this new process: mapping9 the 
LD- RCP flow (figure 1) and establishing baseline perfor-
mance2 on the metrics (figure 2 and table 1). In the SPC 
plot of the weekly blood wastage (the upper graph in 
figure 2), the first 14 datapoints are the preintervention 
period (14 weeks), which gives us the baseline perfor-
mance: a mean wastage of 8.36 units per week (70% of the 
12 delivered each week). Though the system is stable, this 
mean wastage was much higher than we had expected.
Later in the project, we also targeted the age of LD- RCP 
at delivery to RLH (shown in the lower graph in figure 2). 
This is dependent on the NHSBT supplier and was unaf-
fected by our first set of interventions (PDSAs A1 and 
A2, which only changed the flow of blood downstream in 
the process (as shown in figure 1)). Therefore, we could 
use a longer period to establish the preintervention (pre 
PDSAs B1 and B2) performance, though since (as the 
performance is stable (as shown in figure 2)) using the 58 
weeks to estimate this, rather than the 14- week baseline 
period used for wastage, makes little difference. We found 
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baseline performance on this metric to be a median of 
only 42% with age ≤2 days (figure 2 lower graph).
DESIGN
Following analysis of the baseline data, we met to discuss 
the next steps. Though wastage was one of our main 
concerns prior to the start of the study, after reviewing 
the baseline data, it was clearly a bigger problem than we 
had expected.
The ‘WB Programme Group’ was established to eval-
uate new strategies to reduce the LD- RCP wastage, deal 
with other issues arising during the study and feed back 
results and progress to key stakeholders. This was a multi-
disciplinary team (MDT) consisting of the key feasibility 
study members (haematology consultants, emergency 
medicine and trauma consultants, transfusion scientists, 
a research fellow, blood component development scien-
tists and blood component manufacturing specialists). 
As a group, we met every for 4 months to review the 
overall progress of the study and formulate new action 
plans. Key members directly involved in the management 
of LD- RCP delivery and stock management met more 
regularly to discuss compliance and review the data prior 
to the Group’s main meetings.
The main idea was to widen access to the LD- RCP 
beyond the prehospital setting so that a unit approaching 
the end of its shelf life (and so becoming increasingly 
unlikely to be used for the targeted prehospital trans-
fusion) could be used by other patients who could 
benefit. Although the LD- RCP component was devel-
oped mainly for use in the prehospital setting, as noted 
earlier (Background section), the rapid administration 
of this component (which is closer to WB than standard 
RBC) could produce improved outcomes for any major 
trauma patient. Therefore, a natural first target for any 
‘spare’ LD- RCP was patients who present at the ED with 
trauma- induced major haemorrhage. For these patients, 
we expected ED staff to use any LD- RCP available in pref-
erence to RBC. If the wastage level was still above the 
8% target, then a further strategy would be to transfuse 
LD- RCP at the end of its shelf life to other non- trauma 
patients who were bleeding and trauma patients in the 
operating theatre needing ongoing transfusion treatment 
with RBC and thawed plasma as part of routine care.
Figure 1 Process map. Royal London Hospital (RLH) ED, emergency department; KPI, key performance indicator; LAA, 
London’s Air Ambulance; LD- RCP, leucodepleted red cell and plasma; NHS, National Health Service; NHSBT, NHS Blood and 
Transplant; PDSA, Plan–Do–Study–Act.
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As the need for further improvement ideas became 
apparent, we also worked with NHSBT on delivery 
arrangements to increase the opportunity for use by 
increasing the proportion of units delivered at a ‘young’ 
age and coordinating the delivery day so the shelf- life 
window could span two peak- use periods (Fridays and 
Saturdays).
STRATEGY
We wanted to undertake three PDSA projects, but due to 
the COVID-19 pandemic, we were unable to implement 
the third PDSA (ie, transfusing LD- RCP to non- trauma 
patients with bleeding). In the end, we undertook two 
PDSA projects, each with two cycles. Each cycle was 
discussed in the WB Programme Group multidisciplinary 
meetings prior to commencement.
Table 1 summarises the progressive improvement 
cycles: aim, hypothesis, change idea, results and learning. 
The parts of the system changed or targeted are indicated 
on the process map in figure 1, and the results are shown 
on the graphs of the two metrics in figure 2.
The first project (‘Project A’) was to extend the LD- RCP 
pathway by moving remaining units down to the ED 
fridge at 10 days old (only 4 days of shelf life remaining). 
(Note: this never emptied the transfusion lab and HEMS 
stock as by age 10 days a subsequent delivery would have 
occurred, and units were used oldest first.) We pursued 
this change idea first, as it was within our span of control 
in the hospital so could be started immediately; the 
subsequent project (‘Project B’) required discussion with 
NHSBT about their manufacturing and delivery cycles.
The first PDSA cycle (A1) implemented this change 
and tested the impact. It achieved the first (modest and 
interim) target, but there was a long way to go. The study 
phase picked up that ED staff were not always using 
LD- RCP when it was available. A second cycle (A2) was 
therefore initiated, with the trauma research fellows 
(TRFs) working with ED staff with the aim of making 
preferential use of LD- RCP, when available, into routine 
practice. This cycle involved MDT education, targeted 
messaging at handovers, weekly focus on blood transfu-
sion and targeted teaching at new staff induction.
Following this focus on a new pathway to ED use, the 
Group agreed that another reconsideration of the whole 
process was required to attempt to further substantially 
reduce the wastage. Our baseline data highlighted that 
LD- RCP was not being delivered to RLH as fresh as desir-
able: one unit was already 9 days old, so only having 5 days 
of shelf life left (and so, under the new pathway, only 1 day 
for prehospital use before transfer to the ED). Project B 
therefore focused on LD- RCP delivery to RLH to increase 
and adjust its window of availability for use (particularly 
for prehospital use). The weekly LD- RCP delivery had 
been alongside other NHSBT products. We conducted 
Figure 2 Performance metrics over the timeline of the project. ED, emergency department; LD- RCP, leucodepleted red cell 
and plasma; KPI, key performance indicator; PDSA, Plan–Do–Study–Act.
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Table 1 Improvement cycles
PDSA cycle Plan/prediction Do Study Act
Time 
required
Baseline Establish current condition 
(map blood flow and analyse 
baseline performance)
‘Go and see’ 
analysis
KPI: mean weekly 
wastage=8.36 units 
(70%)
PM: median % age 
≤2 days=42% per 
week(oldest=9 days)
Embark on cycles of 
improvement, aiming 
for mean weekly 
wastage less than or 
equal to one unit (8%) 
by November 2020
14 weeks
A1 Transfer near- expiry units to 
the ED
Hypothesis: ED staff can 
make good use of LD- RCP 
for trauma patients
First target: KPI: mean 
weekly wastage=six units 
(50%)
At age=10 days 
move LD- RCP to the 
ED fridge
KPI: mean weekly 
wastage=5.88 units 
(49%)
(PM: median % age 
≤2 days=no change)
Some ED patients 
eligible to receive LD- 
RCP had not, despite 
availability in the ED 
fridge
First target achieved 
but capability low 
(achieved in six out of 
the 8 weeks). Review 
highlighted that further 
work was required: 
conduct another cycle 
with modified plan and 
more ambitious target
8 weeks
A2 Encourage use by ED staff
Hypothesis: trauma research 
fellows (TRFs) could 
establish LD- RCP use as 
routine practice for ED staff
Second target: KPI: mean 
weekly wastage=four units 
(33%)
Existing TRFs work 
in the ED to assist 
with education, 
training and 
prompting use of 
LD- RCP
KPI: mean weekly 
wastage=4.54 units 
(38%)




after a time lag: four 
units achieved most 
weeks in second half 
but capability low (little 
safety margin). Further 
improvement ideas 
needed; tighten target 
a little
26 weeks
B1 Dedicated LD- RCP delivery 
slot
Hypothesis: more LD- RCP 
received at age ≤2 if had 
dedicated delivery slots
Third target: KPI: mean 
weekly wastage=three units 
(25%)
Work closely with 
NHSBT (supplier) 
using RLH metrics 
and data, agree 
dedicated delivery 
slot rather than the 
general delivery slots
KPI: mean weekly 
wastage=3.38 units 
(28%)
PM: median % age 
≤2 days=83% per week
Big improvement in % 
age ≤2 days (process 
metric) but only small 
improvement in mean 
weekly wastage
Further improvement 
ideas needed; tighten 
target a little
13 weeks




incidence highest on Fridays 
and Saturdays, delivery to 
cover 2 weekends would 
decrease wastage
Fourth target: KPI: mean 




Tue: two units, Wed: 
four units, Thu: two 
units, Fri: two units, 
Sat: two units
KPI: mean weekly 
wastage=3.19 units 
(27%) (5 weeks with 
zero wastage)
(PM: median % age 
≤2 days: no change 
expected)
Ultimate target still 
not met, small further 
improvement in mean 
weekly wastage (large 
improvement since 
the start). Variation still 
high
(% age ≤2 days 
appears to continue to 
improve)
17 weeks
C Further extend the LD- RCP 
pathway to include non- 
trauma patients with major 
bleeding.
Hypothesis: will further 
increase in demand for LD- 
RCP.
Fifth target: KPI: mean 
weekly wastage=one unit 
(8%)
Units’ age ≥10 days 
to be also used for 
non- trauma bleeding 
patients in hospital
Could not be 
implemented due to the 
COVID-19 pandemic
ED, emergency department; KPI, key performance indicator; LD- RCP, leucodepleted red cell and plasma; NHSBT, NHS Blood and Transplant; 
PDSA, Plan–Do–Study–Act; PM, process metric; RLH, Royal London Hospital; SPC, Statistical Process Control.
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an improvement cycle (B1) to work with NHSBT to coor-
dinate manufacture and delivery, instituting a dedicated 
LD- RCP delivery. On further analysis and reflection, we 
realised that more trauma cases occurred (and therefore 
more blood was administered) on Friday and Saturday 
than any other days of the week. We therefore ran a 
further cycle (B2) to adjust the LD- RCP delivery schedule 
to allow more units’ 14- day shelf life to span two Fridays 
and Saturdays.
Following the relative success of extending the LD- RCP 
pathway to include ED, we planned a final project 
(‘Project C’) to further extend the use of LD- RCP to 
non- trauma patients with major bleeding. This plan was 
approved in February 2020 by NHSBT and agreed by 
the WB Programme Group for implementation in April 
2020. However, due to the COVID-19 pandemic, we were 
unable to complete this cycle due to lack of resources and 
rapidly changing staffing priorities within the NHS.
RESULTS
Our two main metrics of interest were total component 
wastage (KPI) and age of units on delivery (a process 
metric (PM)), measured on a weekly and monthly basis. 
Baseline data from the beginning of the study prior to any 
interventions demonstrated a stable baseline for meas-
uring weekly component wastage.
As summarised in table 1 and shown in figure 2, over the 
four PDSA cycles, we reduced mean weekly wastage, from 
8.36 units (70%) to 5.88 units per week (49%) and then 
4.54 (38%); 3.38 (28%); and, finally, 3.19 units (27%).
A year after the study started, cycle B1 addressed the 
PM of percentage with age ≤2 days old through changes 
to the transport and delivery arrangements with NHSBT. 
We improved this metric from the baseline of 42%–83%. 
In the lower graph in figure 2, the number of datapoints 
above the new median suggests that performance is 
making further good progress towards an ultimate target 
of 100% of LD- RCP units being delivered at age ≤2 days.
Figure 2 demonstrates that the improvement was 
sustained for the remainder of the trial period (10 
months after the final change). The results from this trial 
(including our design changes to reduce wastage) are 
now being used to plan the next stage of novel compo-
nent supply trials.
Lessons and limitations
The aim of this project was to reduce the wastage level of 
LD- RCP. The two areas of focus were Project A, widening 
access to the blood product (and thus increasing 
demand), and Project B, maximising the useful availa-
bility of the product by adjusting the delivery schedule. 
The total wastage of LD- RCP component was reduced 
over the length of the study. However, although there 
were 17 individual weeks throughout this study period (of 
the total 103 weeks) in which we did manage to achieve 
the target wastage level of less than or equal to one unit, 
we never reached our overall target level of a mean of no 
more than 8%. However, we were unable to implement 
and test the impact of the last QI change idea (ie, trans-
fusing LD- RCP to non- trauma patients in hospital who 
are bleeding).
One area not well investigated in advance was the actual 
demand for blood for major trauma in the prehospital 
setting. The agreement on a constant delivery level of 12 
units per week was based on a quick analysis of HEMS 
Golden Hour box provision rather than a detailed anal-
ysis of historical demand (ie, past use of RBC). Such an 
analysis could have examined weekly demand levels and 
(importantly) its variation, together with any trend and 
longer- term cyclical patterns.
Similarly, prior analysis of within- week demand cycles 
might have prompted, in the setup, design of delivery 
cycles around this and then, in turn, fitting the manu-
facturing schedule to the delivery cycle. This was only 
addressed halfway (a year) through the study, with 
Project B. The widening demand work (Project A) had a 
big impact on wastage (as expected), so starting with this 
seems sensible. However, the length of time until delivery 
root causes were addressed is an example of the conflict 
between (i) very fast- cycle experimentation and improve-
ment and (ii) disentangling the effects of a single change 
(or a single closely related bundle of changes) and being 
able to demonstrate its impacts (eg, with SPC).2 8 This was 
compounded in this study by it being of a new product/
service, so there was felt be no already- existing (histor-
ical) baseline performance data and that new datapoints 
accrued only once a week. The next phase of trials, 
currently being planned, will pick up on this and seek to 
make more effective use of data to predict demand.
In PDSA cycle A1, we unexpectedly found that ED staff 
did not use the new blood product (LD- RCP) whenever 
they could. EDs have many staff, with relatively high turn-
over. Cycle A2 took the remedial step of having TRFs 
working with them to educate and encourage take- up, a 
challenging task in a pressured environment. Our initia-
tive benefitted from their ongoing educational input. 
Other trusts hosting prehospital trauma services gener-
ally have staff in similar roles; alternatively, this task could 
be taken on by dedicated education or transfusion practi-
tioners, which all trusts should have.
The SPC chart highlights that there was a delay in the 
impact seen following the start of this cycle (A2). This lag 
in wastage reduction could demonstrate the time lapse 
between training/education and the application of the 
knowledge gained and in particular could be an example 
of how hard it is to change habits and to establish new 
routines, even with frequent practice and interaction with 
‘coaches’.10
Later, further analysis has established that not all 
LD- RCP wastage had occurred at the end of its shelf life: 
14.1% of LD- RCP units were discarded due to failures in 
cold chain (these units were not kept at the appropriate 
temperature when stored). Furthermore, we also found 
that only 16.5% of transfers of units to the ED occurred 
at the intended 10 days old (and 36% were >12 days old) 
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representing opportunities for further improvement 
within the local system.
More detailed data analysis during the project might 
have picked this up and suggested additional PM. Cold- 
chain failures could have been another target for QI 
cycles, discovering root causes and reducing their inci-
dence. Additional cycles of the ‘Project A’ work (transfer 
to the ED) might have targeted compliance with the 
10- day action point, perhaps considering QI ideas like 
visual management cues, 5S workplace organisation and 
poka yoke mistake proofing.11
In future consideration of blood component flows, 
it would be very useful to institute routine analysis of 
wastage, perhaps with the sort of weekly datapoint SPC 
we have in this study, to monitor patterns (in close to 
real time) and to detect signals of things like changes in 
demand or ED staff practice.
CONCLUSION
Not all the PDSA cycles proved to be as effective in 
reducing the LD- RCP wastage as we expected, and the 
(ambitious) overall target of wastage of less than one unit 
per week (8%) was not achieved. Nevertheless, incre-
mental reductions were demonstrated across the study 
period, reducing the weekly wastage from a mean of 8.36 
units per week (70%) to 3.19 (27%) by the end of the 
study period.
The biggest impact on wastage was making the LD- RCP 
available to be used in the ED and thus increasing the 
demand through cascading what would likely have been 
surplus units to a secondary use. Potential prehospital 
demand for LD- RCP had been very roughly evaluated 
prior to the start of the study. More detailed analysis of 
historical transfusion demand in both prehospital and 
ED settings could have refined this (perhaps obviating 
the need for the B1 and B2 improvement cycles) and also 
stimulated explicit thinking about the trade- off between 
prehospital shortage of LD- RCP (requiring step- down to 
RBC) and prehospital surplus LD- RCP (allowing step- up 
from RBC in the ED and potential final wastage).
A recent review of modelling of perishable blood 
product inventory, in that case platelets, notes that many 
modelling methods have been attempted.12 Our future 
work will concentrate on a deeper level of analysis and 
modelling for our situation. In particular:
 ► Analysis of demand:
 – To evaluate whether the weekly prehospital trauma 
demand can be forecast to a useful extent and with 
what lead time, as can be applied to some other 
emergency- care demand.13 14
 – To consider the use of surplus LD- RCP for other 
bleeding patients (outside of trauma).
 ► Analysis of supply:
 – If weekly demand is forecastable to a useful ex-
tent, to investigate whether it is feasible to insti-
tute a robust system to adjust supply and delivery 
accordingly.
 ► Development of a supply and demand model:
 – To analyse the trade- off between shortage and sur-
plus of LD- RCP, considering both expected (long- 
run average) value and (one- off) risks. This type of 
problem, with uncertain demand and a perishable 
product, is one that has been investigated using op-
erational research modelling,12 15–17 an approach 
that could be useful here.
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